SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Rudenstam Carl Magnus 1930)
 

Search: WFRF:(Rudenstam Carl Magnus 1930) > (1995-1999) > Efficacy of pamidro...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Hultborn, Ragnar,1946Gothenburg University,Göteborgs universitet,Institutionen för särskilda specialiteter, Avdelningen för onkologi,Institute of Selected Clinical Sciences, Department of Oncology (author)

Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study

  • Article/chapterEnglish1999

Publisher, publication year, extent ...

  • 1999

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/45511
  • https://gup.ub.gu.se/publication/45511URI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • PURPOSE: To evaluate the efficacy of pamidronate 60 mg i.v. q 4 weeks in women with advanced breast cancer with skeletal metastases. PATIENTS AND METHODS: 404 woman with skeletal metastases from breast cancer in Sweden and Norway were included in a randomized, placebo-controlled, multicenter study. Except for the study medication, other palliative treatment was chosen at the discretion of the physician. Skeletal related events, i.e. increased pain, treatment of hypercalcemia, pathologic fractures of long bones or pelvis, paralyses due to vertebral compression, palliative radiotherapy for skeletal metastases, surgery on bone and change of antitumor therapy were recorded every third month as well as a self-estimated pain-score using visual Analog Scales and analgesic consumption. RESULTS: There was a significantly increased time to progression of pain (p < 0.01), to hypercalcemic events (p < 0.05) as well as for the cumulative number of skeletal related events (p < 0.01) in favor for the pamidronate group. No statistically significant reduction of pathologic fractures of long bones or pelvis, or pareses due to vertebral compression occurred. No statistically significant differences were found for the need of radiotherapy and surgery on bone. The pamidronate group faired better regarding performance status (p < 0.05). There was a statistically not significant lower consumption of opioid analgesics in the pamidronate group (p = 0.14). CONCLUSION: Pamidronate 60 mg i.v. q 4 weeks reduces skeletal events and improves the quality of life in women with bone metastases from breast cancer.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Gundersen, S. (author)
  • Ryden, S. (author)
  • Holmberg, E. (author)
  • Carstensen, J. (author)
  • Wallgren, U. B. (author)
  • Killany, S. (author)
  • Andreassen, L. (author)
  • Carlsson, G. (author)
  • Fahl, N. (author)
  • Hatschek, T. (author)
  • Sommer, H. H. (author)
  • Hessman, Y. (author)
  • Hornmark-Stenstam, B. (author)
  • Johnsborg, S. (author)
  • Klepp, R. (author)
  • Laino, R. (author)
  • Niklasson, L. G. (author)
  • Rudenstam, Carl-Magnus,1930Gothenburg University,Göteborgs universitet,Institutionen för de kirurgiska disciplinerna,Institute of Surgical Sciences (author)
  • Sundbeck, A. (author)
  • Soderberg, M. (author)
  • Tejler, G. (author)
  • Göteborgs universitetInstitutionen för särskilda specialiteter, Avdelningen för onkologi (creator_code:org_t)

Related titles

  • In:Anticancer Res19:4C, s. 3383-920250-7005

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view